The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2035-2042.PubMedGoogle Scholar 33. Gentzke AS, Wang TW, Jamal A, et al. Tobacco product use ...
FDA itself, however, suggests that a polypeptide is distinguishable from a protein and that the BPCI Act only covers proteins; it is seeking public comment on “develop[ing] a regulatory definition … of [a] protein (as distinguished from a peptide or a polypeptide)” (...
With the FDA enforcing the recall of all ranitidine products, the analysis of nitrosamines particularly NDMA has never been more critical. Nitrosamine impurity in pharmaceuticals drugs found in products of various pharmaceutical vendors...